Third Harmonic Bio announces plan of liquidation and dissolution

Third Harmonic Bio (THRD) announced that the company’s board of directors, after considering opportunities to maximize stockholder value, has approved and adopted a Plan of Liquidation and Dissolution for the liquidation and dissolution of the company and the distribution of remaining cash to stockholders following an orderly wind down of the company’s operations, including any proceeds from a sale of the company’s assets and intellectual property, including but not limited to the THB335 program. Per previous financial and operational guidance, the company will complete all Phase 2 readiness activities for THB335 by mid-year to maximize the value of the program that may be obtained for stockholders in the asset sale process. If its stockholders authorize the dissolution, the company currently plans to file a Certificate of Dissolution with the Secretary of the State of Delaware in the third quarter of 2025. “Our management team and board of directors together have completed an efficient review of our strategic alternatives for maximizing the value of our assets and have determined that returning cash to shareholders and selling our assets, including THB335, is the best path forward,” said Natalie Holles, CEO of Third Harmonic Bio. “We are proud of the work that our team has done over the past years to advance our science, to make tough decisions, and to act with integrity in the best interest of our patients and shareholders.”